We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$731M
AUM Growth
-$365M
Cap. Flow
-$340M
Cap. Flow %
-46.53%
Top 10 Hldgs %
45.16%
Holding
128
New
24
Increased
37
Reduced
18
Closed
39

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.5M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.99M
4
VRNT
Verint Systems
VRNT
+$9.95M
5
STOK icon
Stoke Therapeutics
STOK
+$9.42M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$31.2M
2
NVO
Novo Nordisk
NVO
+$20.9M
3
VTRS icon
Viatris
VTRS
+$13.3M
4
NVS icon
Novartis
NVS
+$9.61M
5
PTCT icon
PTC Therapeutics
PTCT
+$8.3M

Sector Composition

Rank Sector Weight
1 Healthcare 70.2%
2 Technology 11.72%
3 Industrials 2.28%
4 Consumer Discretionary 1.91%
5 Communication Services 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
Johnson & Johnson
JNJ
$618B
$55.7M 7.62%
400,000
+135,000
+51% +$18.7M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$44.1M 6.03%
336,800
+89,500
+36% +$11.5M
BMY icon
3
Bristol-Myers Squibb
BMY
$133B
$42.2M 5.77%
929,900
+50,000
+6% +$2.33M
MRK icon
4
Merck
MRK
$322B
$37.9M 5.18%
473,696
+78,600
+20% +$6.02M
AZN icon
5
AstraZeneca
AZN
$263B
$31.8M 4.35%
385,000
+35,000
+10% +$2.74M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$31.3M 4.29%
2,510,320
+22,242
+0.9% +$282K
VRNT
7
DELISTED
Verint Systems
VRNT
$23.3M 3.18%
849,100
+331,013
+64% +$9.95M
CELG
8
DELISTED
Celgene Corp
CELG
$23.1M 3.16%
250,000
– –
QURE icon
9
CALL
uniQure
QURE
$3.03B
$20.7M 2.83%
265,000
+65,000
+33% +$4.14M
GSK icon
10
GSK
GSK
$104B
$20M 2.74%
400,000
+56,000
+16% +$2.81M
ARQL
11
DELISTED
Arqule Inc
ARQL
$19.6M 2.69%
1,782,643
+350,000
+24% +$2.44M
TEVA icon
12
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$18.9M 2.59%
+2,050,000
New +$24.7M
SRPT icon
13
CALL
Sarepta Therapeutics
SRPT
$1.57B
$18.2M 2.49%
+120,000
New +$14.6M
URGN icon
14
UroGen Pharma
URGN
$1.86B
$11.1M 1.52%
308,377
– –
SEDG icon
15
SolarEdge
SEDG
$2.51B
$10.8M 1.48%
172,762
+53,695
+45% +$2.71M
TVTX icon
16
Travere Therapeutics
TVTX
$5.2B
$10.7M 1.46%
530,678
+95,000
+22% +$1.88M
RETA
17
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$10.6M 1.46%
112,769
+31,000
+38% +$2.68M
STOK icon
18
Stoke Therapeutics
STOK
$1.8B
$9.72M 1.33%
+350,944
New +$9.42M
BLUE
19
DELISTED
bluebird bio
BLUE
$9.54M 1.31%
5,790
-679
-10% -$1.17M
REGN icon
20
Regeneron Pharmaceuticals
REGN
$78.5B
$9.39M 1.28%
+30,000
New +$9.99M
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$9.23M 1.26%
116,000
+16,000
+16% +$1.43M
IFF icon
22
CALL
International Flavors & Fragrances
IFF
$20.2B
$9.21M 1.26%
+63,500
New +$8.82M
ASND icon
23
Ascendis Pharma A/S
ASND
$16B
$8.49M 1.16%
73,773
+5,500
+8% +$658K
CSTE icon
24
Caesarstone
CSTE
$72.3M
$8.09M 1.11%
538,316
+60,202
+13% +$900K
WVE icon
25
Wave Life Sciences
WVE
$1.09B
$8.04M 1.1%
+307,967
New +$8.64M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2019 Portfolio in Review

As of Q2 2019, Sphera Funds Management held 128 positions worth $731M, down 33% from $1.1B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management withdrew a net $340M in Q2 2019, closing 39 positions and reducing 18 holdings. Its most notable exit was Gilead Sciences, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 55% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $9.39M.

  • Sphera Funds Management's largest Q2 2019 buy was Regeneron Pharmaceuticals: 30,000 shares worth $9.39M.
  • Sphera Funds Management added most to Johnson & Johnson in Q2 2019, an estimated $18.7M increase.
  • Sphera Funds Management's biggest Q2 2019 reduction was Viatris, cutting an estimated $13.3M.
  • Sphera Funds Management fully exited Gilead Sciences in Q2 2019, selling an estimated $31.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $731M portfolio in Q2 2019.
  • Sphera Funds Management opened 24 new positions and closed 39 in Q2 2019.
  • Sphera Funds Management's portfolio value fell 33% quarter-over-quarter to $731M.

Based on Sphera Funds Management's 13F filing for Q2 2019, filed 14 Aug 2019.